Today: 28 June 2026
Browse Category

NYSE:ABBV 15 January 2026 - 3 February 2026

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie shares rose 0.8% to $227.55 Tuesday afternoon ahead of its quarterly earnings report due Wednesday morning. The company filed with U.S. and European regulators to expand Rinvoq’s use to non-segmental vitiligo, based on Phase 3 data. Investors are watching whether new immunology drugs can offset Humira’s sales decline.
3 February 2026
···
AbbVie stock rises into weekend as Feb. 4 earnings loom — what traders watch next

AbbVie stock rises into weekend as Feb. 4 earnings loom — what traders watch next

AbbVie shares closed Friday at $223.01, up 1.2%, outpacing big pharma peers as trading volume topped its 50-day average. The company reports earnings Wednesday, with analysts watching Skyrizi, Rinvoq, and the aesthetics segment. AbbVie’s full-year adjusted earnings guidance stands at $9.90 to $9.94. Investors remain cautious amid macroeconomic uncertainty and upcoming U.S. jobs data.
1 February 2026
··
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie shares closed up 0.7% at $220.77 on Monday, moving with broader Wall Street gains ahead of the Federal Reserve’s policy decision and major tech earnings. The company will report full-year and Q4 results before the market opens on Feb. 4. AbbVie recently signed a $650 million cancer drug licensing deal with RemeGen and faces investor scrutiny over its post-Humira growth strategy.
27 January 2026
···
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie shares rose 0.4% to $220.10 Monday, moving between $217.15 and $221.48 as investors awaited its Feb. 4 earnings report. Health-care stocks held firm, with the sector ETF up 0.4% and Johnson & Johnson and Pfizer also gaining. AbbVie’s upcoming results will highlight its immunology drugs as it faces pressure from declining Humira sales and recent policy deals. Traders are watching Wednesday’s Fed decision before the earnings release.
26 January 2026
···
AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
···
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie shares closed up 0.99% at $216.15 Wednesday, trading near typical volume ahead of its Feb. 4 earnings report. Bernstein’s Courtney Breen maintained a Market Perform rating and $225 target. Investors are watching for 2026 guidance and updates on AbbVie’s new drug performance. Details of a recent pricing deal with the Trump administration remain undisclosed.
22 January 2026
·
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
···
1 2 3 4 … 6

Stock Market Today

  • Top UK Dividend Shares for Building Passive Income in 2026
    June 28, 2026, 1:29 PM EDT. As investors seek durable income streams in 2026, established British dividend shares like Diageo, Unilever, and National Grid stand out. These companies have decades-long records of payouts, manageable debt, and strong cash flows supporting dividends. Diageo, with a 4% yield and a 42-year dividend history, is highlighted for its global brands and income reliability amid market uncertainties. Other recommended names include defensive staples and regulated utilities, offering steady or growing dividends without chasing unsustainable high yields. This cautious approach prioritizes long-term dividend growth and cash coverage, making these stocks attractive for passive income portfolios.

Latest articles

US stocks look to jobs data as traders shift from AI tech

US stocks look to jobs data as traders shift from AI tech

28 June 2026
Semiconductor stocks plunged 7.9% last week, their worst performance since April, dragging the S&P 500 down 2.05% as investors pulled nearly $20 billion from tech funds; strategists warn that continued weakness in mega-cap tech could weigh on cap-weighted indexes even as smaller stocks rally, with upcoming jobs data and rate expectations posing further risks.
Go toTop